創新型生物醫藥企業三生國健(688336.SH)將於7月22日在科創板上市
格隆匯 7 月 20日丨三生國健(688336.SH)發佈首次公開發行股票科創板上市公告書,將於2020年7月22日在上海證券交易所科創板上市。
公司成立於2002年,是中國第一批專注於抗體藥物的創新型生物醫藥企業。公司以創新型治療性抗體藥物為主要研發方向,為自身免疫性疾病、腫瘤等重大疾病治療領域提供高品質、安全有效的臨牀解決方案。
發行人主要收入來源為“重組人II型腫瘤壞死因子受體-抗體融合蛋白”(商品名“益賽普”),包括12.5mg/瓶與25mg/瓶兩種規格。益賽普是中國首個上市的全人源抗體類藥物,是中國風濕病領域第一個上市的腫瘤壞死因子(TNF-α)抑制劑,也是中國風濕病領域第一個上市的生物製劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.